These models have good phenotypic data and can be genetically stable and applied to various studies of ophthalmological rare diseases. Meanwhile, our professional and first-class analysis platform can provide the whole process of ophthalmic pharmacodynamic analysis including ocular injection administration, ocular biopsy, ocular tissue sampling, pathology analysis, and molecular testing of gene and protein expression.

• Animal Models for Retinal Degeneration
• Animal Models for Ocular Autoimmune Diseases
• Animal Models for Ocular Neovascularization

At our company, we cater to a global audience of professionals engaged in rare disease drug development and research. Our mission is to support researchers worldwide by offering a comprehensive range of products and preclinical drug development services. Beyond a focus on gene therapy, our diverse portfolio equips researchers with the tools and support needed for every stage of drug development.

Vale Health provides condition specific self-management plans and associated consumer health products for patients to purchase. Content and associated solutions are evidence-based and at the discretion of the health systems. Vale Health pays health systems fair-market-value compensation for their deployment of the platform at their health system.

We exists to give patients self-management support that doctors trust, making health systems more relevant to patients 365 days a year. We do this through a business model that brings new revenue to health systems.

EHR does not provide vetted cash-pay health products to patients.

There are no competitors to our knowledge. Vale Health is a consortium of health systems building the platform together.